论文部分内容阅读
目的:在对非ST段抬高型急性冠脉综合征(ACS)患者进行急诊冠状动脉介入治疗(PCI)时应用国产替罗非班,并对其临床应用的效果与安全性进行观察。方法:选择124例在我院诊断为非ST段抬高型ACS的患者,男90例,女34例,平均分为对照组与观察组,对照组常规进行PCI手术,观察组在手术前给予患者替罗非班,并持续时间达到72 h,经过30 d治疗后,对两组患者血小板的情况,术后的出血情况以及TIMI血流的恢复情况等进行观察。结果:经过治疗后,对照组在心肌梗死的发生率以及ACS血运在重建的发生率方面要高于观察组(P>0.05);在术后TIMⅢ级的比例方面,对照组为81%,明显低于观察组(90%,P<0.05),在血小板的减少情况以及并发症的发生率等方面,对照组也要高于观察组(P>0.05)。结论:在对非ST段抬高型ACS患者的急诊PCI手术之中应用国产替罗非班具有着十分理想的安全性与临床应用效果,能够对患者的心肌微循情况进行改善,减少患者心肌坏死情况的出现,对患者的心脏功能能够起到十分理想的保护效果,并且能够对患者24 h及30 d的病死率进行降低,值得在临床中推广并应用。
Objective: To evaluate the efficacy and safety of domestic tirofiban in the treatment of patients with non-ST-segment elevation acute coronary syndrome (ACS) undergoing emergency coronary intervention (PCI). Methods: A total of 124 patients (90 males and 34 females) diagnosed as non-ST segment elevation in our hospital were selected and divided into control group and observation group. The control group received routine PCI and the control group received preoperative Patients with tirofiban and duration of 72 h, after 30 days of treatment, the two groups of patients with platelet, postoperative bleeding and TIMI blood flow recovery were observed. Results: After treatment, the incidence of myocardial infarction and the incidence of ACS in the control group were higher than those in the observation group (P> 0.05). The percentage of TIM Ⅲ grade in the control group was 81% (90%, P <0.05). The reduction of platelets and the incidence of complications in the control group were also higher than those in the observation group (P> 0.05). Conclusion: The application of domestic tirofiban for emergency PCI in patients with non-ST-segment elevation ACS has a very good safety and clinical effect, which can improve myocardial micro-circulation in patients with myocardial infarction The occurrence of necrosis has a very good protective effect on the patient’s cardiac function, and can reduce the mortality of patients at 24 h and 30 d. It is worth to be popularized and applied clinically.